SLC5A2 and metabolic dysfunction-associated steatotic liver disease: These patients might not have severe insulin resistance that would benefit from SGLT-2 inhibitors, as the proposed mechanism of action for SGLT-2 inhibitors to treat MASLD is through reducing insulin resistance.